Refine by
Locations
- Africa
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo, Democratic Republic Of The
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mali
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Rwanda
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- St. Helena
- Sudan
- Swaziland
- SãO Tomé & PríNcipe
- Tanzania
- Togo
- Tunisia
- Uganda
- Zaire
- Zambia
- Zimbabwe
Heparin Therapy Equipment & Supplies In Africa
5 equipment items found
Manufactured by:Helena Laboratories based in
With a low ISI assignment less than 1.50, this reagent offers reliable sensitivity to liver disease, depression of Vitamin K dependent factors, and coumarin-induced coagulation, even in the presence of high-dose heparin therapy. Open reagent is stable 14 days at ...
Manufactured by:Emosis Diagnostics SAS based inIllkirch-Graffenstaden, FRANCE
HIT Confirm test kit has been CE-marked in March 2018 for the purpose of helping to establish the diagnosis of Heparin-Induced Thrombocytopenia (HIT). The kit is available for research use only (RUO) in non-CE mark regulated countries. HIT is a rare, but life-threatening, disorder that is frequently suspected in hospital in-patients treated with heparin (an ...
Manufactured by:NIKKISO Belgium BV. based inTienen, BELGIUM
Designed for use on the Aquarius™ System, Aquaset™ disposables conveniently combine an Aquamax™ filter with an Aqualine™ ...
Manufactured by:NIKKISO Belgium BV. based inTienen, BELGIUM
Designed for use on the Aquarius™ System with Aquarius+ Software or 6.02.09, CitrasetRCA disposables conveniently combine an Aquamax™ filter with an Aqualine™ RCA ...
Manufactured by:BioMedica Diagnostics based inWindsor, NOVA SCOTIA (CANADA)
ACTICHROME Heparin (Anti-FIIa) is an in vitro diagnostic three-stage assay. It begins with plasmas containing heparin interacting with human antithrombin III to form a heparin-ATIII complex. In the second stage, thrombin is added, which the complex inhibits. The third stage involves the residual thrombin activity hydrolyzing SPECTROZYME TH, a chromogenic substrate. This design ensures that the ...